An improved long-term sales target today revitalised GSK shares after their dismal 2024 ... and distribution networks.

GSK today unveiled a deal to acquire a “potential best-in-class” specialty medicine to treat and prevent progression of steatotic liver disease (SLD). Under the agreement to acquire Boston ...

GSK shares have risen 44p to 1476p after it reiterated full-year guidance and said it is “well positioned” to cope with the impact of any changes to US tariff rules. The reassurance came as ...